Exenatide in Extreme Pediatric Obesity

NCT01237197 on ClinicalTrials.gov · last registry update 2014-09-12

A small phase 2 — 26 participants, against a typical 110. The sponsor logged completion for May 2012. Primary outcome, as filed: Percent Change From Baseline in Body Mass Index at 3-months. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: University of Minnesota
Sponsor type: Other
Enrollment: 26
Started: 2010-10
Primary completion: 2012-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Mass Index at 3-months

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.